FUSEN PHARM(01652): "Compound Potassium Dihydrogen Phosphate Injection" approved for market.

FUSEN PHARM (01652) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has developed the "Compound Potassium Dihydrogen Phosphate Injection" (trademark: Shanweixi), and the application for market approval has been approved by China's National Medical Products Administration as a phosphate supplement. The "Compound Potassium Dihydrogen Phosphate Injection" is mainly used for the treatment of adult and pediatric patients with hypophosphatemia who cannot or have contraindications for oral or enteral nutrition, by supplementing with parenteral nutrition or for those who have low phosphorus levels. As a new generation of phosphorus-potassium compound preparation, the scientific combination of potassium dihydrogen phosphate and dipotassium phosphate can quickly correct phosphorus deficiency, while simultaneously supplementing potassium to stabilize cell membrane potential, preventing the risk of rhabdomyolysis and arrhythmia induced by hypophosphatemia. According to Minet data, the domestic sales of Compound Potassium Dihydrogen Phosphate Injection are expected to reach 343 million yuan in 2023 and 413 million yuan in 2024. The "Compound Potassium Dihydrogen Phosphate Injection" is a Class B medical insurance product listed by the National Healthcare Security Administration, known for its high safety, rapid absorption, dual phosphorus-potassium supplementation, and aligning with multiple guidelines. The company's development of the injection has the same prescription as the original reference product and strict quality control to ensure its quality exceeds or is consistent with the original product, guaranteeing patient safety. The injection provides a favorable risk-benefit ratio for improving laboratory test results and clinical symptoms in adult and pediatric patients with hypophosphatemia and those who require parenteral phosphorus supplementation. Moreover, the "Compound Potassium Dihydrogen Phosphate Injection" is another important product for the group, enriching the group's product pipeline in the field of nutritional supplements. The market launch of this product provides more treatment options for adult and pediatric patients with hypophosphatemia and those who need parenteral phosphorus supplementation.